- French medtech company Vygon signs an exclusive agreement with Carmat to develop a vascular graft compatible with Aeson®, Carmat’s artificial heart.
- Vygon will adapt its existing polythese® vascular graft to connect the Aeson heart to the patient’s arteries.
- The terms of the agreement remain undisclosed, with further device development expected by Q4, 2024.
Uniting MedTech Innovators: Vygon and Carmat Collaboration
Ecouen, France – June 21, 2023 – Vygon, a leading international group specializing in the design, manufacture, and marketing of medical solutions and devices, has announced an exclusive agreement with Carmat, the French medtech company behind the Aeson® artificial heart. Under this partnership, Vygon will develop and manufacture a vascular graft for the artificial heart’s outflow tract, adapting its existing polythese® vascular graft for compatibility with Carmat’s device.
Carmat’s Aeson heart, a world’s first, is a highly hemocompatible, pulsatile, and self-regulated bioprosthetic artificial heart. This innovation holds potential to save thousands of lives each year, offering quality of life and mobility for patients on heart transplant waitlists, thanks to an ergonomic, portable external power supply system.
“We are honored that Carmat has chosen us to develop this new vascular graft – the first of its kind in the world,” commented Ludovic Richard-Vitton, CEO at Vygon. “Carmat is a shining example of French medical innovation and has created a device with real life-saving potential. As fellow medtech specialists, we are proud to join forces with this groundbreaking company.”
Expanding MedTech Horizons: Future Plans
The partnership not only allows Vygon to showcase one of their leading cardiovascular products but also highlights their expertise in problem-solving and innovation. “We’re excited to use our expertise to adapt our graft to Carmat’s requirements and play our part in developing a treatment solution for patients waiting for heart transplants,” said Guillaume Puppinck, Global Director Business Plan and B2B Deployment at Vygon.
Further to this collaboration, Vygon plans to develop a second bespoke device for Carmat by Q4, 2024, under the new agreement.
About Vygon Group
Vygon Group is a world leader in the medical devices industry, providing high-tech single-use medical devices for healthcare professionals in hospitals and for private and independent practitioners. Their portfolio includes products in various clinical specialties, organized in five business units (Critical Care – Neonatology, Enteral & Obstetrics – Intravascular Therapies – Cardiovascular & Surgery – Pain & Airway Management). With global distribution across more than 120 countries, Vygon contributes significantly to the medical sector through innovative products designed for optimum use and safety. For more information, visit www.vygon.com.
Sign up to our newsletter & get the most important monthly insights from around the world.
Ready to Amplify Your Brand with Business Today?
Discover the power of sponsored articles and partnerships to reach decision-makers, professionals, and a dynamic audience. Learn more about our advertising opportunities and connect with us today!
Click here to explore our Promotion & Sponsored Articles page.
Are you looking to make an impact? Contact us at [email protected] to get started!